View of Cost-effectiveness analysis of pemetrexed + cisplatin versus paclitaxel + carboplatin versus paclitaxel + carboplatin + bevacizumab in patients with advanced non-small cell lung cancer without previous treatment

Return to Article Details Cost-effectiveness analysis of pemetrexed + cisplatin versus paclitaxel + carboplatin versus paclitaxel + carboplatin + bevacizumab in patients with advanced non-small cell lung cancer without previous treatment Download Download PDF